2025
SJR Q2
JCR Q2 · 3,2
OA
228 matched articles
SCIE
Journal detail
Neuropsychiatric Disease and Treatment
- Publisher
- Dove Medical Press Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
11782021
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,947
- Quartile Q2
- H-Index 106
- Cites/doc 3,1
- Docs (3y) 723
- Cites (3y) 2.469
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,2
- 5Y JIF 3,6
- JCI 0,76
WoS indexes
- SCIE
Subject classification
Categories (SJR)
Areas
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,947 | 3,2 | 3,6 | 0,76 | Q2 | 106 |
| 2024 | Q2 | Q2 | 0,913 | 2,9 | 3,3 | 0,76 | Q2 | 98 |
| 2023 | Q2 | Q2 | 0,849 | 2,5 | 3 | 0,7 | Q2 | 98 |
| 2022 | Q2 | Q2 | 0,789 | 3,2 | 3,2 | 0,69 | Q2 | 98 |
| 2021 | Q2 | Q3 | 0,774 | 3 | 3,5 | 0,64 | Q3 | 98 |
| 2020 | Q2 | Q3 | 0,819 | 2,6 | 3,2 | 0,62 | Q3 | 98 |
| 2019 | Q2 | Q3 | 0,863 | 2,2 | 2,6 | 0,65 | Q3 | 98 |
| 2018 | — | Q3 | — | 2,2 | 2,7 | 0,65 | Q3 | — |
| 2017 | Q2 | Q3 | 0,911 | 2,2 | 2,5 | 0,64 | Q3 | 98 |
| 2016 | Q2 | Q3 | 0,945 | 2,2 | 2,3 | — | — | 98 |
| 2015 | Q2 | Q3 | 0,777 | 1,9 | 1,9 | — | — | 98 |
| 2014 | Q2 | Q3 | 0,676 | 1,7 | 1,9 | — | — | 98 |
| 2013 | Q2 | Q2 | 0,719 | 2,2 | — | — | — | 98 |
| 2012 | Q2 | Q3 | 0,695 | 2 | — | — | — | 98 |
| 2011 | Q2 | Q3 | 0,652 | 1,8 | — | — | — | 98 |
| 2010 | Q2 | — | 0,521 | — | — | — | — | 98 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | CLINICAL NEUROLOGY | SCIE | Q2 | Q2 | 117/296 |
| 2025 | PSYCHIATRY | SCIE | Q2 | Q2 | 103/293 |
| 2024 | CLINICAL NEUROLOGY | SCIE | Q2 | Q2 | 113/286 |
| 2024 | PSYCHIATRY | SCIE | Q2 | Q2 | 99/288 |
| 2023 | CLINICAL NEUROLOGY | SCIE | Q2 | Q3 | 130/280 |
| 2023 | PSYCHIATRY | SCIE | Q2 | Q2 | 120/279 |
| 2022 | CLINICAL NEUROLOGY | SCIE | Q2 | Q3 | 101/212 |
| 2022 | PSYCHIATRY | SCIE | Q3 | Q2 | 89/155 |
| 2021 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 135/212 |
| 2021 | PSYCHIATRY | SCIE | Q3 | Q3 | 107/155 |
| 2020 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 142/208 |
| 2020 | PSYCHIATRY | SCIE | Q3 | Q3 | 106/156 |
| 2019 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 132/204 |
| 2019 | PSYCHIATRY | SCIE | Q3 | Q3 | 92/155 |
| 2018 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 126/199 |
| 2018 | PSYCHIATRY | SCIE | Q3 | Q3 | 84/146 |
| 2017 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 118/197 |
| 2017 | PSYCHIATRY | SCIE | Q3 | Q3 | 79/142 |
| 2016 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 109/194 |
| 2016 | PSYCHIATRY | SCIE | Q3 | — | 76/142 |
| 2015 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 118/193 |
| 2015 | PSYCHIATRY | SCIE | Q3 | — | 86/142 |
| 2014 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 127/192 |
| 2014 | PSYCHIATRY | SCIE | Q3 | — | 88/140 |
| 2013 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 101/194 |
| 2013 | PSYCHIATRY | SCIE | Q2 | — | 68/136 |
| 2012 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 98/193 |
| 2012 | PSYCHIATRY | SCIE | Q3 | — | 72/135 |
| 2011 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 111/192 |
| 2011 | PSYCHIATRY | SCIE | Q3 | — | 76/130 |